I-Mab (NASDAQ:NBP – Free Report) – Analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of I-Mab in a research note issued to investors on Thursday, August 20th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.08) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for I-Mab’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for I-Mab’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.30) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.70) EPS, FY2029 earnings at ($0.59) EPS and FY2030 earnings at ($0.47) EPS.
I-Mab (NASDAQ:NBP – Get Free Report) last announced its quarterly earnings results on Thursday, August 20th. The company reported ($0.16) earnings per share (EPS) for the quarter.
Check Out Our Latest Stock Analysis on NBP
I-Mab Stock Performance
NASDAQ NBP opened at $1.89 on Monday. The firm has a market cap of $218.58 million, a P/E ratio of -5.25 and a beta of 1.47. I-Mab has a twelve month low of $1.46 and a twelve month high of $6.79. The firm’s fifty day moving average price is $1.79.
Institutional Trading of I-Mab
A hedge fund recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new position in shares of I-Mab (NASDAQ:NBP – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is owned by institutional investors and hedge funds.
About I-Mab
I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.
Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.
Read More
- Five stocks we like better than I-Mab
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.
